Key features and details
- Sensitivity: 0.2 ng/ml
- Range: 0.2 ng/ml - 50 ng/ml
- Sample type: Cell culture supernatant, Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Product nameHuman ErbB 4 ELISA Kit
See all ErbB4 / HER4 kits
Intra-assay Sample n Mean SD CV% Overall < 10% Inter-assay Sample n Mean SD CV% Overall < 12%
Sample typeCell culture supernatant, Serum, Plasma
Assay typeSandwich (quantitative)
Range0.2 ng/ml - 50 ng/ml
Sample specific recovery Sample type Average % Range Serum 75.59 67% - 88% Plasma 75.46 70% - 81% Cell culture media 77.22 67% - 88%
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
Human ErbB 4 ELISA Kit is designed for the quantitative determination of ErbB 4 in cell culture supernatants, plasma and serum samples.
This assay employs an antibody specific for human ErbB 4 coated on a 96-well plate. Standards and samples are pipetted into the wells and ErbB 4 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-human ErbB 4 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of ErbB 4 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
Cross Reactivity: This ELISA kit shows no cross-reactivity with the following cytokines tested: human ADAM-12, ADAM-8, B7H3, Cadherin-13, Cadherin-4, CD155, CD229, CD48, CD58, CD84, CD99, CEACAM-5, Cystatin A, Cystatin B, Cystatin E/M, FGF-21, Galectin-2, Galectin-9, Midkine, Pref-1, SLAM, SP-D, TIM-3, TLR4.
PlatformPre-coated microplate (12 x 8 well strips)
Storage instructionsStore at -20°C. Please refer to protocols.
Components 1 x 96 tests 20X Wash Buffer 1 x 25ml 300X HRP-Streptavidin Concentrate 1 x 200µl 5X Assay Diluent 1 x 15ml Anti-Human ErbB 4 coated Microplate (12 x 8 wells) 1 unit Biotinylated Anti-Human ErbB 4 Detection Antibody 2 vials Human ErbB 4 Standard (Lyophilized) 2 vials Stop Solution 1 x 8ml TMB Substrate Solution 1 x 12ml
FunctionSpecifically binds and is activated by neuregulins, NRG-2, NRG-3, heparin-binding EGF-like growth factor, betacellulin and NTAK. Interaction with these factors induces cell differentiation. Not activated by EGF, TGF-A, and amphiregulin. The C-terminal fragment (CTF) of isoform JMA-A CYT-2 (containing E4ICD2) can stimulate transcription in the presence of YAP1. ERBB4 intracellular domain is involved in the regulation of cell growth. Conflicting reports are likely due at least in part to the opposing effects of the isoform-specific and nuclear-translocated ERBB4 intracellular domains (E4ICD1 and E4ICD2). Overexpression studies in epithelium show growth inhibition using E4ICD1 and increased proliferation using E4ICD2. E4ICD2 has greater in vitro kinase activity than E4ICD1. The kinase activity is required for the nuclear translocation of E4ICD2.
Tissue specificityExpressed at highest levels in brain, heart, kidney, in addition to skeletal muscle, parathyroid, cerebellum, pituitary, spleen, testis and breast. Lower levels in thymus, lung, salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are expressed in cerebellum, but only the isoform JM-B is expressed in the heart.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain.
modificationsIsoform JM-A CYT-1 and isoform JM-A CYT-2 but not isoform JM-B CYT-1 and isoform JM-B CYT-2 are processed by ADAM17. Proteolytic processing in response to ligand or 12-O-tetradecanoylphorbol-13-acetate stimulation results in the production of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 kDa fragments (m80HER4), which are further processed by a presenilin-dependent gamma-secretase to release the respective cytoplasmic intracellular domain E4ICD (either E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2). Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 are more readily degraded by the proteasome than fragments of isoform JM-A CYT-2 suggesting a prevalence of E4ICD2 over E4ICD1.
Ligand-binding increases phosphorylation on tyrosine residues. Isoform JM-A CYT-2 is constitutively phosphorylated on tyrosine residues in a ligand-independent manner. E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues.
Ubiquitinated. The ERBB4 intracellular domain is ubiquitinated and targeted to proteosomal degradation during mitosis mediated by the APC/C complex. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is ubiquitinated, and this involves NEDD4.
Cellular localizationMembrane and Nucleus. Following proteolytical processing E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus.
- Information by UniProt
- Avian erythroblastic leukemia viral oncogene homolog 4
ab267600 has not yet been referenced specifically in any publications.